Precision BioSciences Showcases ARCUS Platform at Mitochondrial Medicine 2024
Precision BioSciences Showcases ARCUS Platform at Mitochondrial Medicine 2024
Precision Biosciences在《線粒體醫學2024年》展示ARCUS平台
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024.
納斯達克公司Precision BioSciences, Inc.（DTIL）是一家先進的基因編輯公司，利用其新型專有的ARCUS平台開發體內基因編輯治療，用於複雜基因編輯，包括基因消除、插入和切除，於2024年6月26日至29日在俄亥俄州克利夫蘭市舉行的United Mitochondrial Disease Foundation（UMDF）Mitochondrial Medicine 2024大會上進行數據展示。